Sign In
Buy INVA
$21.70
+0.350 (+1.64%)
At Close: Jun 03, 2026
SG Americas Securities LLC Raises Position in Innoviva, Inc. $INVA
06:22am, Tuesday, 20'th Jan 2026
SG Americas Securities LLC grew its position in shares of Innoviva, Inc. (NASDAQ: INVA) by 134.4% during the third quarter, according to the company in its most recent disclosure with the Securities a
Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
08:23am, Thursday, 08'th Jan 2026
Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also tend to
Market Today: Tech Slumps, Broadcom Tanks; EU Eases ICE Ban
05:35pm, Friday, 12'th Dec 2025
Stock News Tech-led selloff caps tough week: US stocks fell as investors rotated out of mega-cap tech after Broadcom (AVGO) and Oracle (ORCL) stoked AI-spending
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENC
US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections
01:33pm, Friday, 12'th Dec 2025
The U.S. Food and Drug Administration has approved Innoviva's oral antibiotic for common sexually transmitted infection, offering patients a pill instead of the injection that is currently the only re
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced the publication of positive results from a pivotal Phase 3 trial
Boston Partners Boosts Holdings in Innoviva, Inc. $INVA
04:38am, Saturday, 29'th Nov 2025
Boston Partners lifted its position in shares of Innoviva, Inc. (NASDAQ: INVA) by 40.6% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 875,084 shares of
Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
07:00am, Tuesday, 25'th Nov 2025
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and inf
Innoviva, Inc. (NASDAQ:INVA) Receives Consensus Recommendation of “Moderate Buy” from Analysts
03:11am, Wednesday, 19'th Nov 2025
Innoviva, Inc. (NASDAQ: INVA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven research firms that are presently covering the stock, MarketBeat reports. One inv
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Innoviva, Inc. $INVA
04:36am, Monday, 17'th Nov 2025
Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Innoviva, Inc. (NASDAQ: INVA) during the second quarter, according to the company in its most recent filing with the
Innoviva (INVA) Q3 Earnings and Revenues Beat Estimates
07:41pm, Wednesday, 05'th Nov 2025
Innoviva (INVA) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.02 per share a year ago.
Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
04:05pm, Wednesday, 05'th Nov 2025
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and inf
Strength Seen in Innoviva (INVA): Can Its 5.5% Jump Turn into More Strength?
06:06am, Thursday, 23'rd Oct 2025
Innoviva (INVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
Antheia Appoints Eric d'Esparbes as Chief Financial Officer
08:00am, Tuesday, 21'st Oct 2025
d'Esparbes to lead Antheia's financial strategy as the company continues its global expansionand commercialization MENLO PARK, Calif. , Oct. 21, 2025 /PRNewswire/ -- Antheia , the pharmaceutical ing
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), will share new data on zoliflodacin during the Infectious Disease Society of America's
